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Abstract
Introduction

Serum levels of pro-B-type natriuretic peptide (BNP) and N-terminal (NT) proBNP are measured at admission to assess the likelihood of acutely decompensated heart failure (ADHF).
Elevated NT-proBNP levels on initial presentation are a reliable marker of ADHF. However,
the prognostic significance of NT-proBNP levels measured on admission remains unknown.
With a better understanding of how admitting NT-proBNP levels impacts readmission rates,
length of stay and mortality, future prospective studies with specific interventions can be
developed to reduce all-cause readmissions, shorten length of stay and reduce mortality.
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Methods

In this retrospective study, we evaluated heart failure with reduced ejection fraction
(HFrEF) admissions from 2017–2018 with a focus on 30-, 60- and 90-day all-cause readmissions, length of stay (LOS) and in-hospital mortality rate that are predicted by NT-proBNP
levels measured on admission. Using the HCA Healthcare Enterprise Data Warehouse, adult
patients age 18 to 75 were selected using admission ICD-10 codes for HFrEF. Dialysis patients were excluded. Our search of 90 hospitals yielded 21,445 patients who were stratified
into quartiles depending on their admission NT-proBNP levels: group 1 (<1669 pg/ml), group
2 (1670–4274 pg/ml), group 3 (4275–10,499 pg/ml) and group 4 (>10,500 pg/ml).

Results

Readmission Rates: The 60-day all-cause readmission was significantly (p = 0.047) higher in
group 4 compared to group 1 (adjusted odds ratio (OR) = 1.116, p = 0.013) and group 2 (adjusted OR = 1.111, p = 0.014). The 90-day all cause readmission for group 4 was also significantly
higher when compared to group 1 (adjusted OR = 1.105, p = 0.021).
Length of Stay: Elevated NT-proBNP concentrations were associated with a significantly
longer LOS (p <0.0005). Pairwise, comparisons and estimates for adjusted LOS showed a
positive linear association between higher NT-proBNP groups and longer LOS.
Mortality: Higher inpatient mortality rates were associated with elevated NT-proBNP levels.
The mortality rate was 0.9% in group 1 compared to a 4.7% mortality rate in group 4. Adjusted OR for mortality increased with increasing levels of NT-proBNP.

Conclusions

Based on the analysis, higher admitting NT-proBNP levels were associated with significantly
higher 60-day all-cause readmission, longer LOS and increased mortality. These findings
suggest that measuring NT-proBNP levels at admission may provide an indication of patient
outcomes. Prospective studies with targeted strategies can be developed to reduce readmissions, shorten LOS and reduce mortality based on admission NT-proBNP levels.
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Introduction

Serum levels of pro-B-type natriuretic peptide (BNP) and N-terminal (NT) pro-BNP are
routinely measured at the time of admission
for patients with shortness of breath to assess
the risk of acutely decompensated heart failure
(ADHF). Pro-BNP, released by the myocardium due to cardiac wall distention, is cleaved
into the active BNP and inactive NT-proBNP
forms.1 Elevated levels of NT-proBNP are a
reliable marker of ADHF,2 but the time of measurement varies, which could be affected by
treatment. Fisher et al. found that NT-proBNP
levels, measured just prior to discharge, were
predictive of mortality and readmission.3 Flint
et al. examined NT-proBNP levels at the time
of discharge and observed that patients with
levels >1000 ng/L had a 15% higher 30-day
readmission rate.4 The levels of NT-proBNP
are expected to be more stable at discharge
after patients have been treated for ADHF
and, therefore, may not accurately reflect the
ventricular function.1 Measuring NT-proBNP at
admission, when the patient is acutely ill and
seeking treatment, may be more predictive of
patient outcomes. However, the prognostic
significance of the levels of NT-proBNP at the
time of initial admission remains unknown.1,3
With a better understanding of how admitting
NT-proBNP levels impacts all-cause readmission rates, length of stay (LOS) and mortality,
further prospective studies are warranted to
develop specific interventions during systolic heart failure admissions to reduce length
of stay, mortality and reduce readmissions.
The purpose of this study was to determine
whether NT-proBNP, measured on patient
admission, provided an indication of outcome
when a patient was admitted for HFrEF. We
hypothesized that patients with higher levels
of NT-proBNP would have higher readmission
rates, longer length of stay and higher rates of
mortality.

Methods

Study Design

In this retrospective study, we evaluated heart
failure with reduced ejection fraction (HFrEF)
admissions from 2017–2018. We also analyzed
30-, 60- and 90-day all-cause readmission
rates, LOS and mortality rate and compared
them to the NT-proBNP levels at the time of
admission. Using the HCA Healthcare En208

terprise Data Warehouse (EDW), we identified patients aged 18 to 75 years old using
admitting ICD-10 codes for acute systolic
heart failure. Dialysis and patients under the
age of 18 were excluded, and our extraction
yielded 21,445 patients. These patients were
grouped into quartiles based on the admission NT-proBNP levels: group 1 (<1,669 pg/ml),
group 2 (1,670–4,274 pg/ml), group 3 (4,275–
10,499 pg/ml) and group 4 (>10,500 pg/ml).

Patient Population

Our patient population includes those 18 to 75
years of age who were admitted from January 2017 to December 2018 with an admitting
ICD-10 code for HFrEF. Dialysis patients were
excluded.

Outcomes

The primary outcomes of interest were allcause readmission rate, length of stay and
mortality.

Statistical Analysis

In order to summarize patient characteristics
and comorbidities, descriptive statistics were
used. Multivariate comparisons of patient
characteristics, comorbidities and outcomes
(all-cause readmission, LOS and mortality)
were conducted. Statistical significance was
evaluated using α = 0.05. Multiple logistic regression was performed to identify differences
in readmissions and mortality. Adjusted odds
ratios and p-values between BNP groups were
calculated from these multiple logistic regression analyses. LOS analysis was done with an
ANCOVA model with post hoc pairwise comparisons.

Results

Demographics Data

Table 1 summarizes the demographics for
patients (n = 21,445) included in the data set.
Sample patients were more likely to be Caucasian males (63.2%) with the average age ranging from 60–62.9 years among the quartiles.
The highest comorbidities within the study
group were coronary artery disease (CAD),
diabetes mellitus (DM), COPD, chronic kidney
disease (CKD) and obesity (BMI >30). Regarding CKD, higher levels of NT-proBNP were associated with a glomerular filtration rate (GFR)
of <44 mm/min.
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Table 1. Demographics.
Group 1
NT-proBNP
<1,669
(n = 5,360)

Group 2
NT-proBNP
1,670–4,274
(n = 5,362)

Group 3
NT-proBNP
4,275–10,499
(n = 5,362)

Group 4
NT-proBNP
>10,500
(n = 5,361)

Age
Average age (years)
(mean +SD)

<0.0005
60.0 +10.75

60.8 +10.95

61.7 +10.76

62.9 +10.35

Sex
Male

p Value

<0.0005
3,742 (69.8%)

3,801(70.8%)

3,684 (68.7%)

3,355 (62.5%)

Race

0.026

Caucasian

3,728 (69.6%)

3,614 (67.4%)

3,605 (67.2%)

3,654 (68.1%)

African American

1,199 (22.4%)

1,332 (24.8%)

1,279 (23.9%)

1,261 (23.5%)

433 (8.1%)

416 (7.8%)

478 (8.9%)

446 (8.3%)

HTN

920 (17.2%)

809 (15.1%)

746 (13.9%)

505 (9.4%)

<0.0005

ACS

77 (1.4%)

65 (1.2%)

56 (1.0%)

56 (1.0%)

0.192

PCI during hospital
stay

73 (1.4%)

73 (1.4%)

77 (1.4%)

97 (1.8%)

0.170

2,729 (50.9%)

2,732 (51.0%)

2,871 (53.5%)

3,039 (56.7%)

<0.0005

Atrial fibrillation

933 (17.4%)

1,204 (22.5%)

1,165 (21.7%)

1,010 (18.8%)

<0.0005

Prior ICD

754 (14.1%)

784 (14.6%)

773 (14.4%)

760 (14.2%)

0.848

Prior pacemaker

352 (6.6%)

351 (6.5%)

373 (7.0%)

349 (6.5%)

0.769

1,839 (34.3%)

1,746 (32.6%)

1,802 (33.6%)

1,903 (35.5%)

0.012

411 (7.7%)

320 (6.0%)

352 (6.6%)

283 (5.3%)

<0.0005

1,189 (22.2%)

1,821 (34.0%)

2,356 (43.9%)

3,631 (67.7%)

<0.0005

4,632 (86.4%) 4,238 (79.0%)

3,779 (70.5%)

2,190 (40.9%)

<0.0005

Other
Medical History

CAD

COPD
Asthma
CKD
Admission GFR: ≥45
Admission GFR: 30-44

508 (9.5%)

757 (14.1%)

990 (18.5%)

1,194 (22.3%)

Admission GFR: 15-29

191 (3.6%)

322 (6.0%)

469 (8.7%)

1,097 (20.5%)

Admission GFR: <15

29 (0.5%)

45 (0.8%)

124 (2.3%)

880 (16.4%)

Diabetes mellitus

2,607 (48.6%)

2,677 (49.9%)

2,556 (47.7%)

Obesity (BMI>30)

1,025 (19.1%)

884 (16.5%)

751 (14.0%)

529 (9.9%)

<0.0005

Alcohol abuse

199 (3.7%)

260 (4.8%)

210 (3.9%)

175 (3.3%)

<0.0005

Tobacco abuse

99 (1.8%)

102 (1.9%)

102 (1.9%)

105 (2.0%)

0.981

2,789 (52.0%) <0.0005

Abbreviations: HTN: hypertension, ACS: acute coronary syndrome, PCI: percutaneous coronary intervention, CAD:
coronary artery disease, ICD: implantable cardioverter-defibrillator, COPD: chronic obstructive pulmonary disease, CKD:
chronic kidney disease, GFR: glomerular filtration rate, BMI: body mass index

All-cause Readmission Rates

The 30-day all-cause readmission rates were
26.7, 26.9, 27.7 and 30.6% respectively for the
quartiles (groups 1–4). The 60-day readmission
rates were 37.4, 37.8, 39.3 and 42.8% respec-

tively for the quartiles. The 90-day readmission
rates were 42.9, 43.8, 48.2 and 48.2% respectively. The 60-day readmission rates, however,
were the only statistically significant readmission period (p = 0.047).
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Figure 1. All-cause readmission rate by NT-proBNP group.
Intra-group analysis showed that group 4
(NT-proBNP >10,500) had a significantly higher
rate of 60-day all cause readmission compared
to group 1 (adjusted odds ratio (OR) = 1.116, p

= 0.013) and group 2 (adjusted OR = 1.111, p =
0.014). Group 4 was also significantly higher
than group 1 (adjusted OR = 1.105, p = 0.021) for
90-day readmission (Figure 1 and Table 2).

Table 2. All-cause Readmission Rates by NT-proBNP.
30 Day Readmission Rate: p = 0.202
Adjusted Odds Ratio
BNP(a)\BNP(b)

1,670–4,274

4,275–10,499

>10,500

<1,669

0.997 (p = 0.947)

1.029 (p = 0.522)

1.092 (p = 0.066)

1,670–4,274

-

1.032 (p = 0.474)

1.095 (p = 0.051)

-

-

1.062 (p = 0.185)

4,275–10,499

60 Day Readmission Rate: p = 0.047
Adjusted Odds Ratio
BNP(a)\BNP(b)

1,670–4,274

4,275–10,499

>10,500

<1,669

1.005 (p = 0.904)

1.052 (p = 0.212)

1.116 (p = 0.013)

1,670–4,274

-

1.047 (p = 0.252)

1.111 (p = 0.014)

4,275–10,499

-

-

1.061 (p = 0.154)

90 Day Readmission Rate: p = 0.115
Adjusted Odds Ratio
BNP(a)\BNP(b)

1,670–4,274

4,275–10,499

>10,500

<1,669

1.029 (p = 0.474)

1.064 (p = 0.118)

1.105 (p = 0.021)

1,670–4,274

-

1.035 (p = 0.385)

1.075 (p = 0.088)

4,275–10,499

-

-

1.039 (p = 0.355)

The 60-day readmission rates were the only statistically significant readmission period (p = 0.047). Intra-group analysis
showed that group 4 had a significantly higher rate of 60-day all cause readmission compared to group 1 (adjusted OR
= 1.116, p = 0.013) and group 2 (adjusted OR = 1.111, p = 0.014). Group 4 also was also significantly higher than group 1
(adjusted OR = 1.105, p = 0.021) for 90-day readmission.
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Figure 2. Average length of stay by NT-proBNP group. (LOS: length of stay)

Length of Stay

Length of stay showed a positive linear association of a higher length of stay with increasing
NT-proBNP levels. The median length of stay
was 4.67, 5.39, 5.91 and 7.03 days respectively
for groups 1, 2, 3 and 4. Pairwise, comparisons
for adjusted LOS showed a positive correlation
between the higher NT-proBNP groups and a
longer LOS with a p <0.0005. (Figure 2)
Mortality
In-hospital mortality rate increased with higher quartiles of admission NT-proBNP levels.
In-hospital mortality rates were 0.9, 1.4, 2.5
and 4.7% for groups 1, 2, 3 and 4 respectively (p
<0.0005). (Figure 3) Computing adjusted OR
for mortality within each group revealed progressively higher OR across the groups. Most
notably, group 4 had a 4.789 adjusted OR for
mortality compared to group 1 (p <0.0005),

3.013 odds compared to group 2 (p <0.0005)
and 1.802 adjusted OR for death compared to
group 3 (p <0.0005). (Table 3)

Discussion

Our primary aim in this study was to identify
NT-proBNP levels that would predict readmission rates, length of stay (LOS) and mortality.
We found that patients in the highest quartiles
of NT-proBNP on admission had statistically
higher 60-day all-cause readmission rates, longer LOS and higher mortality rates. Most patients in our data set were noted to be Caucasian males (68%) with coronary artery disease
(CAD) (53%), chronic kidney disease (CKD)
(42%), diabetes mellitus (DM) (49.6%), chronic
obstructive pulmonary disease (COPD) (34%)
and obesity with a body mass index >30kg/m2
(14.9%) as their most common co-morbidities.
As expected, higher levels of NT-proBNP were
252
(4.7)

Mortality (N(%))

300
250
200
150
100
50
0

46
(0.9)

Group 1

133
(2.5)

77
(1.4)
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p <0.0005
Mortality (N)

Figure 3. In-hospital mortality rates by NT-proBNP group.
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Table 3. Mortality.
Adjusted Odds Ratio
BNP(a)\BNP(b)

1,670–4274

4,275–10,499

>10,500

<1,669

1.589 (p = 0.014)

2.657 (p <0.0005)

4.789 (p <0.0005)

1,670–4,274

-

1.672 (p <0.0005)

3.013 (p <0.0005)

4,275–10,499

-

-

1.802 (p <0.0005)

In-hospital mortality rate increased with higher quartiles of admission NT-proBNP level. Group 4 had a 4.789 adjusted
OR for mortality compared to group 1 (p <0.0005), 3.013 odds compared to group 2 (p <0.0005) and 1.802 adjusted OR
for death compared to group 3 (p <0.0005). Group 3 had a 2.657 adjusted OR compared to group 1 (P <0.0005) and
1.672 adjusted OR compared to group 2 (p <0.0005). Group 2 had an adjusted OR of 1.589 compared to group 1 (p =
0.014).

noted with levels of GFR <44 milliliters per
minute on admission.
Several researchers have used NT-proBNP
to assess patient outcomes, but most have
used NT-proBNP measured at least 24 hours
after admission or at discharge [5-9]. Some
researchers reported that higher levels of BNP
are related to increased rates of readmission.5,6
Noveanu et al. measured NT-proBNP during the
24 hours after admission and did not observe
significant changes in the first 24 hours of admission. This lack of change may be caused by
delayed kinesis of NT-proBNP.7
Bettencourt et al. reported a “positive association between pattern of change in NT-proBNP and time to readmission or death among
patients discharged in low New York Heart
Association (NYHA) class and without signs of
volume overload”.8 Nunez et al. demonstrated
that BNP had a significant predictive value for
readmission if mortality was excluded.9 In the
above-mentioned studies, BNP levels were
obtained either at least 24 hours after admission or prior to discharge.7-9 Collectively, these
researchers showed that BNP was effective for
predicting patient readmission.5,6,9 Consistent
with these previous findings, increasing levels
of admission NT-proBNP, as seen in the highest
2 quartiles of our study (groups 3 and 4), were
associated with an increased risk of 60-day allcause readmission.
We speculate that patients with higher levels of admission NT-proBNP are likely to have
more severe acute exacerbations. NT-proBNP
levels could adversely be influenced by coexisting medical conditions such as CAD, CKD and
DM. The levels may be elevated in CAD due to
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myocardial ischemia and the resultant reduced
cardiac dysfunction.7,10 Renal dysfunction is a
strong predictor of a poor prognosis in heart
failure patients. These poor outcomes are likely
due to multifactorial pathophysiology, including
decreased renal perfusion, venous congestion
and neurohumoral activation.7 Magnusson et
al. suggested that elevated NT-proBNP levels
in patients with DM was due to DM-associated asymptomatic left ventricular dysfunction.11
Furthermore, DM is a well-known risk factor
for CAD and CKD. Thus, patients in the highest quartiles, especially with these comorbidities, impose a higher potential burden on the
healthcare system given the resources required
to treat these patients. Our data suggests that
physicians should remain vigilant of readmissions beyond 30 days. Knowing the admission
NT-pro-BNP could help clinicians identify these
patients that will have worse outcomes and
ensure appropriate follow up is recommended. More attentive outpatient follow-up with
a primary care physician or cardiologist could
reduce the probability of readmission.
Based on the results of the present study,
admission NT-proBNP level could help estimate expected LOS, which may be utilized to
address patient expectations and the required
hospital resources. Our data suggests that independent of the factors mentioned in Table 1,
LOS progressively increased with higher levels
of NT-proBNP. Using admission NT-proBNP
levels in patients admitted for HFrEF may help
hospitals estimate expected LOS (Figure 2) to
better predict through put and allocate adequate resources.
Our study revealed a significantly increased risk
of mortality in admission NT-proBNP quartiles
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3 and 4. Núñez et al. reported a similar positive
association with mortality. However, Nunez et
al. measured the NT-proBNP levels after the
patients became clinically stable.9 In the FAST,
GUSTO IV and FRISC II trials, NT-proBNP levels
were strong, independent predictors of mortality.10 Increased risks of all-cause mortality
(relative risk (RR) 4.7, 95% CI 2.0–10.9) for levels
of proBNP above the median was noted during
the 18-month follow-up in the trial from the
Australia-New Zealand Heart Failure Group.12
The Valsartan Heart Failure (Val-HeFT) trial reported an increased adjusted risk of mortality
(3.8%) and hospitalization (3%) for each increment of 500 ng/L above the baseline proBNP.13
In support of these Val-HeFT trial findings,
Noveanu et al. noted that NT-proBNP levels
measured at admission, 24 hours, 48 hours and
discharge were higher in 1 year non-survivors
compared to survivors. However, NT-proBNP
levels at 24 or 48 hours did not predict 30-day
mortality.7 Overall, our study suggests that
increasing admission NT-proBNP levels are associated with worsening rates of mortality.
Many studies evaluating the prognostic value of
BNP have been conducted, but there are a limited number of trials examining the correlation
between NT-proBNP levels and readmission
rates, LOS or mortality. The levels of NT-proBNP are expected to be more stable at discharge
following treatment. Therefore, discharge
NT-proBNP levels may not accurately reflect
the degree of heart failure exacerbation, how
critically ill the patients are and, subsequently,
their predisposition to readmission, longer LOS
or increased mortality. Further prospective trials studying the correlation between NT-proBNP levels and rehospitalization are warranted.
Limitations
Our study has several limitations. First, patients were identified using discharged ICD-10
codes through an electronic administrative
database. The accuracy of the ICD-10 codes is
dependent on multiple factors: quality of communication between physicians and patients,
clinicians’ expertise and precision of the diagnoses in medical records and coders’ experience and attention to choosing the best code.
Hence, as an administrative database, the
HCA Healthcare EDW may have variations
in degree of detail and accuracy. Second,

NT-proBNP levels can be elevated due to
other causes such as hypertrophic cardiomyopathy, pericarditis, pulmonary hypertension,
etc. These conditions may co-exist with heart
failure exacerbations, leading to exaggerated elevations of NT-proBNP. Finally, patients
returning to hospitals outside the HCA Healthcare
system could affect readmission rates, and
their readmits would not be included in our
data set. However, with over 20,000 patients
in our data set who are most likely to return
to the hospital where they received their initial treatment, we assume that this effect is
minimal. Nevertheless, we cannot account for
patients whose initial visit was, for example,
during travel or for patients who live in urban
areas with multiple hospitals.

Conclusion

Patients in the quartiles 3 (4275–10,499 pg/ml)
and 4 (>10,500 pg/ml) of admission NT-proBNP
had statistically higher 60-day all-cause readmission rates, longer LOS and higher mortality
rates. Given these results, patients with higher levels of NT-proBNP on admission would
likely benefit from more aggressive inpatient.
Future prospective studies are warranted to
develop more aggressive treatment protocols
depending on admission NT-proBNP and the
effect on readmission rates, LOS and mortality. During their inpatient stay, physicians and
hospitals can better anticipate LOS and inpatient mortality. They should extensively educate
patients regarding their medical condition and
prognosis. Patients should be provided detailed
discharge instructions about lifestyle modifications and medication compliance. Close outpatient follow-up with a primary care physician
and cardiologist is also crucial to reducing readmission rates. Further prospective studies for
admission NT-proBNP levels above 4275 pg/ml
with direct interventions are warranted to determine if LOS and mortality can be improved
in the higher NT-proBNP groups.
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